التفاصيل البيبلوغرافية
| العنوان: |
Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry |
| المؤلفون: |
Francuzik, W. Ruëff, F. Bauer, A. Bilò, M.B. Cardona, V. Christoff, G. Dölle-Bierke, S. Ensina, L. Fernández Rivas, M. Hawranek, T. O'B Hourihane, J. Jakob, T. Papadopoulos, N.G. Pföhler, C. Poziomkowska-Gęsicka, I. Van der Brempt, X. Scherer Hofmeier, K. Treudler, R. Wagner, N. Wedi, B. Worm, M. |
| سنة النشر: |
2021 |
| الوصف: |
Background: Venom-induced anaphylaxis (VIA) is a common, potentially life-threatening hypersensitivity reaction associated with (1) a specific symptom profile, 2) specific cofactors, and 3) specific management. Identifying the differences in phenotypes of anaphylaxis is crucial for future management guidelines and development of a personalized medicine approach. Objective: This study aimed to evaluate the phenotype and risk factors of VIA. Methods: Using data from the European Anaphylaxis Registry (12,874 cases), we identified 3,612 patients with VIA and analyzed their cases in comparison with sex- and age-matched anaphylaxis cases triggered by other elicitors (non-VIA cases [n = 3,605]). Results: VIA more frequently involved more than 3 organ systems and was associated with cardiovascular symptoms. The absence of skin symptoms during anaphylaxis was correlated with baseline serum tryptase level and was associated with an increased risk of a severe reaction. Intramuscular or intravenous epinephrine was administered significantly less often in VIA, in particular, in patients without a history of anaphylaxis. A baseline serum tryptase level within the upper normal range (8-11.5 ng/mL) was more frequently associated with severe anaphylaxis. Conclusion: Using a large cohort of VIA cases, we have validated that patients with intermediate baseline serum tryptase levels (8-11 ng/mL) and without skin involvement have a higher risk of severe VIA. Patients receiving β-blockers or angiotensin-converting enzyme inhibitors had a higher risk of developing severe cardiovascular symptoms (including cardiac arrest) in VIA and non-VIA cases. Patients experiencing VIA received epinephrine less frequently than did cases with non-VIA. © 2020 American Academy of Allergy, Asthma & Immunology |
| اللغة: |
English |
| URL الوصول: |
https://explore.openaire.eu/search/publication?articleId=od______2127::8870ab2d002ab007661ce4ee0de55d4a
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3003261 |
| حقوق: |
OPEN |
| رقم الأكسشن: |
edsair.od......2127..8870ab2d002ab007661ce4ee0de55d4a |
| قاعدة البيانات: |
OpenAIRE |
